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Running title: Streptococcal prosthetic joint infection 
 
 
Summary 
Rate of failure among 462 patients with streptococcal periprosthetic joint infection 
managed with implant retention was 42.1% (95% confidence interval:37.5%–46.7%). 
Treatment with β-lactams was confirmed to improve the prognosis, which could be 
improved by the addition of rifampin. 
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ABSTRACT  
Background: Streptococci are not an infrequent cause of periprosthetic joint infection 
(PJI). Management by debridement, antibiotics, and implant retention (DAIR) is 
thought to produce a good prognosis, but little is known about the real likelihood of 
success. 
Methods: Retrospective, observational, multicenter, international study performed 
during 2003-2012. Eligible patients had a streptococcal PJI that was managed with 
DAIR. The primary endpoint was failure, defined as death related to infection, 
relapse/persistence of infection, or the need for salvage therapy. 
Results: Overall, 462 cases were included (median age 72 years, 50% men). The most 
frequent species was S.agalactiae (34%), and 52% of all cases were hematogenous. 
Antibiotic treatment was primarily using β-lactams, and 37% of patients received 
rifampin. Outcomes were evaluable in 444 patients: failure occurred in 187 (42.1%, 
95% confidence interval: 37.5%–46.7%) after a median of 62 days from debridement; 
patients without failure were followed for a median of 802 days. Independent 
predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical 
infection (2.20), and bacteremia (1.69). Independent predictors of success were 
exchange of removable components (0.60), early use of rifampin (0.98 per day of 
treatment within the first 30 days), and long treatments (≥21 days) with β-lactams, 
either as monotherapy (0.48) or in combination with rifampin (0.34). 
Conclusions: this is the largest series of streptococcal PJI managed by DAIR, showing a 
worse prognosis than previously reported. The beneficial effects of exchanging the 
removable components and of β-lactams are confirmed, and maybe also a potential 
benefit from adding rifampin.  
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BACKGROUND 
Periprosthetic joint infection (PJI) is a dreaded complication of joint replacement [1,2]. 
Removal of the infected foreign body is the rule for any given device-associated 
infection. However, debridement, antibiotics, and implant retention (DAIR) may be 
attempted in some acute cases of PJI [2-4]. When strict selection of patients is 
followed, the success rate may reach >85% [4-7]. 
 
Streptococci are responsible for PJI in 4–12% of cases [8,9] especially in hematogenous 
infections [10,11]. Some studies have suggested that streptococcal PJI may have a 
more favorable outcome compared with other etiologies [12-14], but this has been 
contested by others [15]. In fact, the success rate of streptococcal PJI (mostly 
Streptococcus agalactiae) treated with DAIR varies from 22–100%, presumably 
depending on the selection criteria used [6,13,15-18] (Supplementary Table 1). Thus, 
the real success rate for patients managed by DAIR remains uncertain.  
 
The optimal antimicrobial treatment for streptococcal PJI is also unknown. Current 
guidelines recommend the use of β-lactams [2,4], but these antibiotics may have a 
very high minimal biofilm eradication concentration [19,20]. The role of alternative 
compounds with a better antibiofilm profile [21] has not been consistently explored in 
clinical studies.  
 
Our aim was to analyze the clinical presentations and outcomes of a large cohort of 
patients with streptococcal PJI managed by DAIR, focusing on the impact of 
antimicrobial therapy. 
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METHODS 
Setting and Patients 
This was a multicenter retrospective study performed in 52 hospitals from 15 nations 
between 2003 and 2012. Patients were included if they had suffered a PJI that was 
caused by streptococci and initially managed by DAIR. Eighty-one cases included here 
have previously been published [6,15,22]. 
PJI was defined according to IDSA guidelines as the presence of a sinus tract 
communicating with the prosthesis, acute inflammation on histologic examination, 
purulence surrounding the prosthesis, and/or ≥2 evaluable samples yielding the same 
organism [4]. Polymicrobial cases were also included if streptococci were isolated from 
the beginning, but we excluded cases of streptococcal superinfection. Microorganisms 
were identified following standard criteria [23], after samples had been inoculated in 
liquid and solid media and incubated for ≥7 days. Enterococci, obligate anaerobes (i.e. 
Peptostreptococcus spp) or nutritionally variant streptococci (i.e. Abiotrophia spp) 
were not included.  
  
PJI was classified as early postoperative, if the symptoms began within the first 3 
months after the prosthesis was placed, and late post-surgical, if they started 
thereafter. The episode was considered acute hematogenous, if it occurred after an 
uneventful postoperative course and after microbiologically confirmed or clinically 
suspected streptococcal bacteremia. A contiguous spread was considered, if the PJI 
occurred in a limb with either infectious cellulitis, or a soft tissue abscess. New 
radiographical signs of infection were taken as a surrogate marker of chronicity (i.e., 
periprosthetic radiolucency, bone sclerosis, or osteolytic lesions). Chronic renal failure 
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was defined as a baseline creatinine >150 µmol/L; immunosuppressant therapy was 
recorded if the patient received was receiving glucocorticoid or other 
immunosuppressant drug therapy 
 
Data were recorded in a Microsoft-Access database. All cases were critically reviewed 
by one author (J.L-T.), and any doubts or inconsistencies were double-checked by the 
investigator at each hospital.  
 
Clinical and Surgical Management 
DAIR has been described elsewhere [2,3,24]. Briefly, it comprises thorough surgical 
debridement of all purulent collections and necrotic tissues surrounding the 
prosthesis. Mobile parts of the device (i.e. the polyethylene liner) are exchanged if 
feasible. DAIR is recommended in patients who meet the criteria proposed by the IDSA 
guidelines [4]. Patients with early postoperative (<1 month) or acute hematogenous PJI 
with ≤3 weeks of symptoms qualify for DAIR if they have a soundly fixed prosthesis, 
good periprosthetic soft tissues condition, and antibiotics are available with a 
reasonable activity against biofilm-embedded bacteria. In the present study, these 
criteria were not strictly met by many patients, and the decision to undergo DAIR was 
taken by individual medical group on a case by case basis.  
 
Outcome and Follow-up 
Patients were followed until death, treatment failure, removal or replacement of the 
prosthesis, or until loss to follow-up. Overall Failure was the primary endpoint and was 
considered in cases of: i) death related to the infection; ii) need for salvage therapy to 
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control the infection, including supplementary surgical debridements >30 days after 
the first debridement, prosthesis removal (due to any cause during the first year after 
debridement, or due to streptococcal persistence or relapse, or superinfection by 
other microorganisms), or the need for supplementary courses of antibiotics beyond 
the initially scheduled treatment (including chronic suppressive antimicrobial therapy); 
and/or iii) persistent signs of infection at the last visit or follow-up appointment. 
 
Given the retrospective nature of this study, and to avoid a survivor bias when 
analyzing the impact of antimicrobial therapy, several failure dynamics were studied: 
 Early Failure was considered to have occurred in patients who met the failure 
criteria within the first 30 days after surgical debridement.  
 Late Failure was considered to have occurred in patients who met the failure 
criteria beyond the first 30 days after debridement, but who were still under 
antimicrobial therapy. In this group, only antimicrobials received during the first 30 
days were analyzed.  
 Failure after Therapy was considered to have occurred in patients who met the 
failure criteria once they had finished the scheduled therapy. In this analysis, the 
antibiotics received throughout treatment were included. 
 
Statistical Analysis 
Categorical parameters were compared with the χ2 test or Fisher’s exact test, and 
continuous variables were compared with the Mann–Whitney U test or Kruskal–Wallis 
test. Parameters associated with Overall Failure, Late Failure, and Failure after Therapy 
were identified by Kaplan–Meier curves (long-rank test), univariate, and multivariate 
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Cox regression. For the analysis of Early Failure, logistic regression were performed.  
All analyses were 2-tailed, and a p value <0.05 was considered statistically significant.  
 
RESULTS 
Description of the Series 
Overall, 922 cases of PJI were recorded, of which 92 (10.0%) were excluded for various 
reasons, leaving a cohort of 830 cases. We initially managed 462 (55.7%) by DAIR, and 
these cases were used as the focus of this analysis (Supplementary Figure 1). 
 
The median age was 72 years (interquartile range [IQR] 65–78 years), and 50% were 
men. The most frequent type of PJI was hematogenous (52%), which occurred more 
frequently in men, in patients with malignancy and in those with knee prostheses. 
Patients with hematogenous PJI more frequently presented with bacteremia and 
elevated temperature, along with higher leukocyte counts and C-reactive (CRP) protein 
levels (Table 1).  
 
The most frequent species was S. agalactiae (159 cases [34.4%]) (Table 2). There were 
63 (14%) polymicrobial infections which were typically postoperative (83%), presented 
less frequently with fever (51% vs 68%, p=0.007) and more frequently with a sinus 
tract (34% vs 10%, p<0.001), and had lower CRP levels (80 mg/L [IQR 41-150] vs 202 
mg/L [IQR 110-291], p<0.001). 
 
Baseline features, clinical presentation, and management were similar among the 
streptococcal species (Supplementary Table 2). Exceptions to this were the higher rate 
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of patients with rheumatoid arthritis among episodes caused by S. pyogenes, and the 
higher rate of chronic lung disease and malignancy in PJI due to S. pneumoniae. 
Pneumococcal PJI was also more frequently hematogenous, occurred more frequently 
with knee prostheses, and presented with a higher leukocyte count. Penicillin 
minimum inhibitory concentration (MIC) was >0.125 mg/L in 24/425 cases (6%). 
 
DAIR Management 
Patients underwent debridement after a median of 5 days (IQR 2–13) from the onset 
of symptoms. Removable components were exchanged in 53% of cases, this being 
highly variable across participating centers (Supplementary Figure 2). The median 
number of different antimicrobial classes prescribed per patient was 2 (range 1–6). 
Patients were usually treated with β-lactams, which were given intravenously for a 
mean time of 21 days ± 20 days. Rifampin-based combinations were significantly used 
(i.e. during >21 days) in 37% of patients, but this fraction was also highly variable 
across the participating hospitals (in those recruiting >10 patients, it ranged from 18–
88%) (Supplementary Figure 2). Alternative antimicrobials such as fluoroquinolones, 
clindamycin, or linezolid were used less often (Supplementary Table 3). In patients not 
failing while on treatment, antimicrobial therapy was continued for a median of 91 
days (IQR 58–171 days).  
 
Outcome 
The primary endpoint was evaluable in 444 patients (96.1%). Overall Failure occurred 
in 187 patients (42.1%, 95% confidence interval [95%CI]: 37.5%–46.7%) after a median 
of 62 days from debridement (IQR 25–160 days); by contrast, 257 patients (57.1%) did 
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not fail and were followed up for a median of 802 days (IQR 507–1339 days) (Figure 1-
A). Success rates were highly variable among the participating centers (Supplementary 
Figure 2), with it ranging from 44% to 91% among hospitals recruiting >10 patients. 
 
Independent predictors of a poor outcome were rheumatoid arthritis (Hazard Ratio 
[HR] 2.36), late post-surgical infection (HR 2.20), and bacteremia (HR 1.69). The 
exchange of removable components was independently associated with a favorable 
outcome (HR 0.60) (Table 3). No one streptococcal species was associated with a 
higher likelihood of Overall Failure, although a non-significant better prognosis was 
observed for S.pneumoniae (24% failure). A high penicillin MIC ( >0.125 mg/L) was also 
not associated with failure. Also, polymicrobial cases were not associated with a higher 
likelihood of failure, even when S.aureus was involved (data not shown).  
 
Late post-surgical infection was indeed a predictor of bad prognosis, when defined as 
onset of symptoms beginning >3 months after the prosthesis placement (Figure 1-C). 
Cases with symptoms beginning within the first and third month had a similar 
prognosis to that of cases with symptoms beginning within the first month after 
prosthesis placement. No relevant differences were observed in these two groups of 
patients (data not shown). 
  
The failure rate was higher in patients not fulfilling the IDSA criteria for DAIR, namely  
106/223 (48%) vs 81/221 (37%) (long-rank test, p=0.017) (Fig 1-B). Again, indication of 
DAIR according to the IDSA criteria was highly variable among participating centers 
(Supplementary Figure 2), ranging from 33% to 83% in those recruiting >10 patients. 
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Independent predictors of failure among patients meeting the IDSA criteria were 
rheumatoid arthritis (HR 2.46 [95%CI 1.34–4.53]), bacteremia (HR 1.92 [95%CI 1.22–
3.02]), and male sex (HR 1.85 [95%CI 1.18–2.91]). Interestingly, the exchange of 
removable components during debridement was especially beneficial in patients not 
meeting the IDSA criteria (37% failures vs 62%, p<0.001), in comparison with patients 
fulfilling them (failures 33% vs 39%, p=0.286).  
 
Failure Dynamics and Antimicrobial Therapy 
Among the 187 patients who failed, 55 (29%) developed Early Failure, 71 (38%) 
developed Late Failure, and 61 developed Failure after Therapy (33%). Variables 
independently associated with Early Failure were age, rheumatoid arthritis, late post-
surgical infection, bacteremia, and infection by S.pyogenes (Table 4). 
 
Characteristics associated with Late Failure were male sex, immunosuppressant 
therapy, revision prosthesis, debridement delay >7 days, and the need for >1 
debridement to control the infection. Failure was also associated with the early use of 
glycopeptides during >14 days. However, the addition of rifampin to treatment with 
glycopeptides neutralized this poor prognosis. The early use of rifampin plus 
fluoroquinolones also showed a trend toward a favorable outcome in the univariate 
analysis (HR 0.19, p=0.082). 
 
Late post-surgical infection was an independent predictor of Failure after Therapy, 
while the exchange of removable components was associated with a favorable 
outcome. The use of β-lactams for >21 days, both alone and combined with rifampin, 
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were independently associated with better outcomes (HR 0.48 and 0.34, respectively) 
(Figure 2).  
The benefits of early treatment with rifampin were also observed for patients when 
treatment did not fail within the first 30 days after debridement (HR 0.98 per day of 
treatment, p=0.034) (Table 3).  
 
DISCUSSION 
This is the largest series assessing the management of streptococcal PJI by DAIR. Our 
results show an overall long-term likelihood of curing the infection and keeping the 
prosthesis of 57%. The large sample used in our study, the diversity of streptococcal 
species, and the high number of participating hospitals increase the external validity of 
our results. 
 
Predictors of a poor outcome in this series were similar to those found in previous 
studies of PJI by staphylococci and GNB managed by DAIR. In previous reports, patients 
with bacteremia, needing >1 debridement, or with high CRP levels have shown to have 
a bad prognosis [24-29]. In our series, bacteremia and infection by S.pyogenes were 
independent predictors of Early Failure. 
 
Otherwise, the streptococcal species presented a very similar pattern regarding clinical 
presentation and outcome, though S.pneumoniae presented more frequently as a 
hematogenous infection, and was usually associated with a better prognosis (non-
significant).  
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The percentage of hematogenous infection in this series was notably high, when 
compared with PJI by S.aureus (52% vs 15%) [25]. Moreover, we cannot rule out that 
some late post-surgical infections were actually hematogenous. Although 
staphylococcal hematogenous PJI has been reported to carry a poor prognosis 
[25,30,31], in this study we did not find an association with failure, despite the higher 
association of hematogenous infection with bacteremia, fever, high levels of CRP, and 
a high leukocyte count. It is possible that the ability of β-lactams to clear bacteremia 
and planktonic infection in hematogenous PJI could be higher for streptococci than for 
staphylococci. 
 
Univariate and multivariate analyses have shown that some debilitating baseline 
conditions are associated with a worse outcome. Taken together with our previous 
large series, rheumatoid arthritis, immunosuppressant therapy, and chronic renal 
insufficiency seem to be associated with a higher risk of treatment failure when 
attempting DAIR [25,27]. The exchange of removable components was associated with 
a favorable outcome, something that has also been observed in previous studies 
[25,32]. This is consistent with the physical removal of the biofilm, and probably stands 
as a surrogate marker of an exhaustive surgical debridement. Of note, this benefit was 
particularly observed in patients not fulfilling IDSA criteria for DAIR. 
 
Unfortunately, the possibility of performing an accurate analysis of antimicrobial 
efficacy is impaired by the retrospective nature of this study, along with the 
heterogeneity of the therapeutic schedules. Still, the large size of our series allows for 
some interesting considerations. 
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Β-lactams have classically been the preferred therapy for streptococcal infections, 
including PJI, providing very good activity for the initial planktonic phase of these 
infections [33]. However, once this initial phase has passed, the antibiofilm profile of 
these antimicrobials is questionable because, as with any antibiotic with a mechanism 
of action dependent on cell wall synthesis, they will become less effective against 
biofilm-embedded bacteria [34]. There is now strong evidence β-lactams have poor 
efficacy for staphylococcal and GNB PJI, especially when contrasted with other 
antibiotics that have superior antibiofilm profiles, such as rifampin against 
staphylococci or fluoroquinolones against GNB [25-27,35,36]. However, these findings 
have not been demonstrated in streptococcal PJI, which haves been disregarded in 
those studies. 
 
Our patients were mostly treated with β-lactams, in line with classic recommendations 
and routine clinical practice. The multivariate analysis concerning Failure after Therapy 
showed that this therapy was beneficial, with superiority over less effective 
alternatives like glycopeptides. This beneficial effect probably depended, in part, on 
the activity of β-lactams against planktonic bacteria in the first weeks of treatment 
[37]. Therefore, this contribution may be relevant to the outcome of PJI.  
 
However, other data could indicate the suboptimal antibiofilm activity of β-lactams in 
our series, along with some evidence of a possible beneficial effect of rifampin. Among 
patients who completed a long course of treatment with β-lactams, we did not 
observe statistical differences among those also receiving rifampin or not, but a 
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tendency toward a better prognosis was found in those treated with combined 
therapy (10.0% failure rate vs 16.8%, Fig 2). In addition, the initial treatment with 
rifampin was also proved as an independent predictor of a favorable outcome (Table 
4). 
 
IDSA criteria for instituting DAIR were not met by all cases in this study. Consistent 
with previous studies, this allowed us to confirm the usefulness of these criteria for 
selecting suitable candidates for DAIR [6,7,25,27]. We were also able to test the effect 
of each of these criteria on the outcomes. In this regard, the duration of symptoms 
may be difficult to establish, especially in postoperative cases where pain and 
inflammation may overlap those of the post-surgical period. The age of the prosthesis 
may therefore be a more objective measure in such cases, consistent with the IDSA 
recommendation that patients undergo DAIR only if there is a short time between the 
prosthesis placement and debridement [4]. The definition of early postoperative PJI 
has varied over time in several landmark publications, ranging from 1 to 3 months 
[2,11,36], with the IDSA recommending that DAIR should be performed within 1 month 
after placing the prosthesis [4]. However, we have observed a similar prognosis for 
patients with postoperative infection whose symptoms began within the first month 
after prosthesis placement and those whose symptoms started between the first and 
third month (Fig 2). A similar finding was also observed for staphylococcal PJI [25], and 
it would emphasize this 3-month time limit over a more strict cutoff. 
 
As mentioned, our analysis has the inherent limitations of retrospective studies. For 
instance, the influence of antibiotics was evaluated with continuous variables (i.e. days 
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of antibiotics), but also after arbitrarily categorizing these parameters (i.e., >21 days of 
treatment). Also, the possible relevance of endocarditis was not evaluated in this 
study. Finally, it has been already mentioned the significant heterogeneity of patients 
included across the participating institutions, especially regarding their management: 
the fulfillment of the IDSA criteria, the participation of different surgical teams or the 
decision on whether to use or not rifampin are all examples of this 
variability  (supplementary figure 2). Still, these cases form a large cohort of patients 
with streptococcal PJI, all treated by DAIR. This has given us the opportunity to study 
their prognosis in the best and the worst possible clinical scenario,  thus providing an 
overall perspective of the clinical problem. 
 
In summary, we analyzed the largest series of streptococcal PJI managed by DAIR to 
date, and showed a modest prognosis of curing the infection and retaining the 
prosthesis. We conclude that classical treatment with β-lactams is probably ideal for 
fighting the planktonic component of the infection. We found a piece of evidence 
suggesting that addition of rifampin some days or weeks after debridement could 
improve the outcome, but this should be confirmed in further studies. IDSA criteria are 
a valid clinical tool for deciding DAIR, late post-surgical infection (i.e. symptoms 
beginning >3 months since prosthesis placement) being the most important contra-
indication. The exchange of removable components during debridement stands as an 
independent predictor of a favourable outcome.
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Figure 1 – Kaplan-Meier curves of patients with streptococcal periprosthetic joint 
infection according to the criteria for indicating debridement and implant retention 
A – Kaplan-Meier curve of all evaluable patients (n=444, 187 failures). Causes of 
failure were due to the streptococcal infection in 147 cases (79%), the other reasons 
being prosthesis removal due to orthopedic causes (15 patients [8%]), and 
superinfection by other microorganisms (25 cases [13%]). Death related to PJI was 
observed in 11 cases (2%).  
 
B – Black continuous line: patients meeting IDSA criteria for DAIR (see text): 81 
failures in 221 episodes of infection; grey dotted line: patients not meeting IDSA 
criteria for DAIR: 106 failures in 223 episodes of infection; long-rank test, p = 0.017. 
Reasons for not fulfilling the IDSA criteria were (more than 1 motive per patient is 
possible): in 67 patients (30%) symptoms duration was longer than 21 days; 90 patients 
(40%) had a post-surgical infection with symptoms beginning beyond the first month 
after the placement of the prosthesis; 61 patients (27%) presented with a sinus tract; and 
in 80 cases (36%) there were radiographic signs of prosthesis loosening and/or chronic 
infection. 
C - post-surgical cases (i.e., non-hematogenous cases) (n=189, 82 failures): black 
continuous line: cases with symptoms beginning within the first 30 days after the 
placement of the prosthesis (n=78, 25 failures); grey continuous line: cases with 
symptoms beginning within 31 and 90 days after the placement of the prosthesis (n=41, 
13 failures); black dotted line: cases with symptoms beginning beyond 90 days after the 
placement of the prosthesis (n=70, 44 failures). Long-rank test, p<0.001. 
 
 
Figure 2 – Prognostic after the end of therapy according to the antibiotic treatment 
Analysis performed in cases that did not fail during treatment (n=318, failures = 61). 
Black continuous line: patients treated during >21 days with β-lactams + rifampin 
(n=60, failures=6); black dotted line: patients treated during > 21 days with β-lactams, 
but no rifampin (n=154, failures=26); grey continuous line: patients treated >21 days 
with a rifampin-based combination other than β-lactams plus rifampin (n=48; 
failures=10); grey dotted line: patients who did not receive either β-lactams or rifampin 
for > 21 days (n=56; failures=19). Comparisons calculated with the Long-rank test. The 
comparison of these 4 treatment regimes showed similar trends when the analysis was 
stratified for patients meeting and not meeting IDSA criteria, and for patients who did 
and did not undergo exchange of removable components during debridement. 
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Table 1 – Baseline features, clinical presentation, surgical management and 
outcome and comparative analysis of hematogenous and non-hematogenous cases 
  All patients 
(n=462) 
Non-hematogenous 
cases (n=220) 
Hematogenous  
cases (n=242) 
p 
Baseline features     
 Sex (men) 232 (50%) 121 (45%) 111 (54%) 0.050 
 Age (years)^ 72 (65-78) 72 (64-78) 72 (65-78) 0.986 
 Diabetes 111 (24%) 50 (23%) 61 (25%) 0.533 
 Renal chronic disease 45 (10%) 20 (9%) 25 (10%) 0.654 
 Rheumatoid arthritis 37 (8%) 15 (7%) 22 (9%) 0.369 
 Immunosuppressive therapy 49 (11%) 22 (10%) 27 (11%) 0.687 
 Malignancy 29 (6%) 7 (3%) 22 (9%) 0.009 
 Liver cirrhosis 19 (4%) 9 (4%) 10 (4%) 0.982 
 Chronic lung disease 56 (12%) 27 (12%) 29 (12%) 0.924 
 Chronic heart disease 128 (28%) 54 (25%) 74 (31%) 0.148 
 Prosthesis location (knee) 273 (59%) 117 (53%) 156 (65%) 0.014 
 Revision prosthesis 114 (25%) 48 (22%) 66 (27%) 0.174 
Clinical presentation and microbiological data    
 Temperature >37⁰ C 300 (66%) 110 (51%) 190 (80%) <0.001 
 Sinus tract 62 (14%) 46 (21%) 16 (7%) <0.001 
 Leukocyte count (x10E9/L)^ 12.0 (8.5-15.4) 11.0 (7.3-14.6) 13.0 (9.6-16.0) 0.001 
 C-reactive protein at diagnosis 
(mg/L)^ 
186 (85-283) 135 (55-230) 234 (130-305) <0.001 
 Rx signs of infection 85 (18%) 41 (19%) 44 (18%) 0.900 
 Bacteremia 138 (31%) 35 (17%) 103 (45%) <0.001 
 Penicillin MIC >0.125 mg/L § 24/425 (6%) 15 (8%) 9 (4%) 0.113 
 Polymicrobial infection 63 (14%) 52 (24%) 11 (5%) <0.001 
Surgical management     
 Time to debridement (days)^
ф
 5 (2-13) 5 (2-16) 5 (2-12) 0.688 
 Exchange of removable 
components 
&
 
220/418 (53%) 100/200 (50%) 120/218 (55%) 0.302 
 Need for ≥2 debridements 42 (9%)  21 (10%) 21 (9%) 0.797 
Outcome‡     
 Overall failure 187/444 (42%) 92/210 (44%) 95/234 (41%) 0.494 
 Early failure‡ 55/187 (29%) 25/92 (27%) 30/95 (32%) 0.509 
 Late failure‡ 71/187 (38%) 34/92 (37%) 37/95 (39%) 0.779 
 Failure after therapy ‡ 61/187 (33%) 33/92 (36%) 28/95 (30%) 0.351 
Data expressed as count and (percentage) except for ^continuous variables (median and interquartile range). 
MIC: minimal inhibitory concentration.
 ф
Time from onset of symptoms to surgical debridement. 
&
Data 
available in 418 cases. ‡444 patients evaluable for outcome, percentages given over the whole of failures. 
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Table 2 – Etiology of 462 episodes of streptococcal periprosthetic joint infection 
Streptococcus    
 S. agalactiae  159 
(34.4%)  S. pyogenes  36 (7.8%) 
 S. pneumoniae  21 (4.5%) 
 Other large-colony β-haemolytic streptococci  121 
(26.2%)   S. dysagalactiae 49 
(10.6%) 
 
  Group G streptococci 40 (8.7%)  
  Other β-haemolytic streptococci 28 (6.1%)  
  S. equisimilis 4 (0.9%)  
 S. anginosus group  32 (6.9%) 
  S. anginosus 17 (3.7%)  
  S. constellatus 8 (1.7%)  
  S. milleri 4 (0.9%)  
  S. intermedius 3 (0.6%)  
 Viridans group  86 (18.6%) 
  Unspecified viridans streptococci 25 (5.4%)  
  S. mitis 25 (5.4%)  
  S. oralis 17 (3.7%)  
  S. sanguis 10 (2.2%)  
  S. salivarius 4 (0.9%)  
  S. gordonii 2 (0.4%)  
  S. mutans 2 (0.4%)  
  S. parasanguis 1 (0.2%)  
 Other streptococci  7 (1.5%) 
  S. bovis 6 (1.3%)  
  S. canis 1 (0.2%)  
     
Other microorganisms (polymicrobial episodes)   
 Gram positive microorganisms  59 
  Staphylococcus aureus 29   
  Coagulase-negative staphylococci^ 15  
  Enterococcus faecalis 7   
  Corynebacterium striatum^ 2   
  Other Gram-positive microorganisms* 6   
 Gram negative microorganisms  19 
  Enterobacteriaceae† 15   
  Non-fermentative Gram-negative 
bacilli** 
2  
  Anaerobe Gram-negative 
microorganisms‡ 
2   
     
*includes Aerococcus viridans (n=1), Arcanobacterium haemolyticus (n=1), Bacillus spp 
(n=2), Lactobacillus acidophilus (n=1) and Peptostreptococcus spp (n=1);  ** includes 
Pseudomonas aeruginosa (n=1), Acinetobacter baumannii (n=1); † includes Escherichia 
coli (n=5), Klebsiella pneumoniae (n=1), Enterobacter cloacae (n=4), Proteus mirabilis 
(n=3), Serratia sp (n=1), and Citrobacter sp (n=1); ‡includes Veillonella spp, and Prevotella 
spp
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Table 3 – Predictors of Overall Failure and Influence of Early Antibiotic 
 
 
All evaluable cases – Overall Failure 
 (n=444, 187 failures) 
Evaluable cases not failing within the first 30 days  
(n=389, 132 failures)  
Variable Categories Failures/n HR (95%CI) P aHR  (95%CI) P Failures/n HR (95%CI) P aHR (95%CI) P 
Sex Female 90/225 0.86 (0.65-1.14) 0.30   60/195 0.75 (0.53-1.06) 0.10 - - 
Male* 97/219     72/194     
Age (per year) - - 1.00 (0.99-1.01) 0.93   - 0.99 (0.98-1.01) 0.32   
Diabetes Yes 50/108 1.16 (0.84-1.60) 0.38   36/94 1.20 (0.82-1.76) 0.36   
No* 137/336     96/295     
Renal Chronic 
Disease 
Yes 24/44 1.58 (1.03-2.43) 0.05 1.55 (0.97-2.48) 0.07 16/36 1.57 (0.93-2.65) 0.09 - - 
No* 163/400     116/353     
Rheumatoid arthritis Yes 24/37 2.23 (1.45-3.43) <0.01 2.36 (1.50-3.72) <0.01 14/27 2.04 (1.17-3.54) 0.02 - - 
No* 163/407     118/362     
Immunosuppressive 
therapy 
Yes 29/48 1.86 (1.25-2.76) <0.01 - - 21/40 2.08 (1.31-3.32) <0.01 1.66 (0.99-2.18) 0.055 
No* 158/396     111/349     
Malignancy Yes 11/28 0.90 (0.49-1.66) 0.73   10/27 1.20 (0.63-2.29) 0.59   
No* 176/416     122/362     
Prosthesis location Knee 116/263 1.05 (0.95-1.16) 0.31   82/229 1.09 (0.91-1.29) 0.36   
Other* 71/181     50/160     
Revision prosthesis Yes 60/112 1.60 (1.18-2.17) <0.01 1.37 (0.98-1.90) 0.06 42/94 1.66 (1.15-2.40) <0.01 1.47 (0.99-2.18) 0.06 
No* 127/332     90/295      
Hematogenous  
infection 
Yes 95/234 0.90 (0.68-1.20) 0.48   65/204 0.84 (0.60-1.18) 0.32   
No* 92/210     67/185     
Late post-surgical 
infection 
Yes 44/70 1.41 (1.19-1.67) <0.01 2.20 (1.51-3.20) <0.01 31/57 1.28 (1.12-1.46) <0.01 1.69 (1.10-2.60) 0.02 
No* 143/374     101/332     
Temperature >37⁰ C Yes 122/288 1.08 (0.79-1.46) 0.65   85/251 1.05 (0.73-1.52) 0.78   
No* 60/149     42/132     
Sinus tract Yes 27/61 1.12 (0.75-1.69) 0.58   21/55 1.29 (0.81-2.06) 0.30   
No* 155/378     107/330     
Rx signs of infection Yes 39/80 1.08 (0.99-1.19) 0.11   25/66 1.21 (0.77-1.91) 0.42   
No* 98/251     72/225     
Leukocytes (per unit/µL) - 1.00 (1.00-1.00) 0.21   - 1.00 (1.00-1.00) 0.11   
C-reactive protein Per mg/L - 1.00 (1.00-1.00) 0.91   - 1.00 (1.00-1.00) 0.76   
Penicillin MIC 
 
>0.125 mg/L 8/23 0.80 (0.40-1.63) 0.53   4/19 0.58 (0.21-1.56) 0.24   
≤0.125 mg/L* 161/384     111/334     
30 
 
Bacteriemia Yes 63/132 1.44 (1.06-1.96) 0.02 1.69 (1.19-2.40) <0.01 39/108 1.23 (0.84-1.79) 0.30   
No* 110/290     83/263     
Polymicrobial 
infection 
Yes 28/59 1.17 (0.78-1.74) 0.46   21/52 1.27 (0.80-2.03) 0.32   
No* 159/385     111/337      
Time to 
debridement† 
Per day - 1.00 (1.00-1.00) 0.06 - - - 1.00 (1.00-1.00) 0.01 1.00 (1.00-1.00) 0.05 
>7 days 82/173 1.28 (0.96-1.71) 0.09   61/152 1.45 (1.03-2.05) 0.03   
≤ 7 days* 105/271     71/237     
> 21 days 35/67 1.33 (0.92-1.92) 0.14   27/59 1.51 (0.99-2.31) 0.07   
≤ 21 days* 152/377     105/330      
Polyethylene 
exchange 
Yes 73/211 0.59 (0.44-0.80) <0.01 0.60 (0.44-0.81) <0.01 53/191 0.60 (0.42-0.86) <0.01 0.65 (0.50-0.93) 0.02 
No* 98/190     68/160     
Need for ≥2 
debridements 
Yes 41/80 1.41 (1.00-2.00) 0.05 1.38 (0.96-1.99) 0.08 30/69 1.53 (1.02-2.30) 0.05 1.68 (1.10-2.57) 0.02 
No* 146/364     102/320     
Treatment with 
rifampin‡ 
Per day - -    - 0.99 (0.97-1.00) 0.05 0.98 (0.96-0.998) 0.03 
>14 days - -    33/116 0.72 (0.48-1.06) 0.09   
≤14*days - -    99/273     
Treatment with 
β-lactams‡ 
Per day - -    - 0.99 (0.98-1.01) 0.99   
>14 days - -    87/270 0.85 (0.59-1.22) 0.39   
≤14* days - -    45/119     
Treatment with 
glycopeptides‡ 
Days - -    - 1.04 (1.02-1.06) <0.01 1.04 (1.02-1.06) <0.01 
>14 days - -    16/29 2.37 (1.40-4.00) <0.01   
≤14* days - -    116/360     
Treatment with co-
trimoxazole‡ 
Days - -    - 1.03 (1.00-1.06) 0.04 1.04 (1.002-1.08) 0.04 
>14 days - -    6/9 2.33 (1.03-5.30) 0.04   
≤14* days - -    126/380     
HR: Hazard Ratio; aHR: adjusted Hazard Ratio. 95%CI: 95% confidence intervals. CPR: C-reactive protein. MIC: minimal inhibitory concentration. * reference 
category. †Time from onset of symptoms to surgical debridement‡Treatments considered are those received within the first 30 days after surgical debridement. 
Overall analysis does not include the influence of antibiotics in order to avoid survivors bias. The initial model of the multivariate analyses was built with variables 
with a P value ≤0.10 in the univariate analysis, and then selected with a stepwise backward process (variables excluded during this process are marked as “-“). 
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Table 4 – Univariate and multivariate analysis of parameters predicting Early Failure, Late Failure and Failure After Therapy  
  Early failure (n=444, 55 failures)
a
  Late Failure (n=389, 71 failures)
b
     Failure After Therapy (N=318, 61 failures)
c
 
    
  OR (CI95%) p aOR (95%CI) p  HR (95%CI) p aHR (CI95%) p  HR (95%CI) p aHR (CI95%) p 
Sex (female) 1.19 (0.68-2.10) 0.540    0.50 (0.31-0.81) 0.004 0.51 (0.30-0.85) 0.009  1.16 (0.69-1.92) 0.572   
Age (per year) 1.03 (0.99-1.01) 0.076 1.04 (1.00-1.07) 0.027  1.00 (0.98-1.02) 0.995    0.99 (0.97-1.01) 0.348   
Rheumatoid arthritis 2.98 (1.35-6.56) 0.007 3.33 (1.40-7.93) 0.007  2.95 (1.55-5.62) 0.004 - -  1.19 (0.37-3.81) 0.772   
Immunosuppressive therapy 1.49 (0.66-3.66) 0.343    2.76 (1.56-4.89) 0.002 2.64 (1.46-4.79) 0.001  1.51 (0.65-3.51) 0.363   
Renal chronic disease 1.67 (0.73-3.81) 0.223    1.99 (1.05-3.79) 0.053 - -  1.17 (0.47-2.91) 0.746   
Prosthesis location (knee) 1.04 (0.86-1.26) 0.677    0.98 (0.83-1.14) 0.753    1.18 (0.98-1.41) 0.073 - - 
Revision prosthesis 1.53 (0.83-2.81) 0.173    1.78 (1.09-2.91) 0.027 1.77 (1.07-2.93) 0.027  1.56 (0.90-2.70) 0.129   
Chronic post-surgical inf. 1.212 (0.97-1.23) 0.091 1.41 (1.10-1.81) 0.007  1.12 (0.92-1.37) 0.256    1.47 (1.22-1.77) <0.001 2.24 (1.24-4.05) 0.008 
Sinus tract 0.75 (0.31-1.84) 0.529    1.05 (0.54-2.06) 0.881    1.61 (0.84-3.11) 0.175   
Bacteremia 2.17 (1.20-3.92) 0.011 2.23 (1.80-4.20) 0.014  1.24 (0.74-2.06) 0.420    1.23 (0.70-2.19) 0.478   
Rx signs of infection 1.16 (0.98-1.39) 0.091 - -  0.77 (0.40-1.48) 0.421    2.21 (1.14-4.30) 0.025 - - 
Infection by S. pyogenes 3.10 (1.41-6.85) 0.005 3.31 (1.41-7.77) 0.006  0.60 (0.19-1.92) 0.357    1.11 (0.45-2.78) 0.821   
Infection by virdidans streptococci 0.71 (0.32-1.57) 0.401    1.60 (0.94-2.70) 0.094 - -  1.01 (0.51-1.98) 0.987   
Polymicrobial infection 0.95 (0.41-2.20) 0.896    1.33 (0.71-2.47) 0.385    1.23 (0.61-2.49) 0.579   
Time to debridement  (>7 days)† 0.96 (0.54-1.72) 0.899    1.60 (1.00-2.54)† 0.050 1.70 (1.05-2.75) 0.033  1.33 (0.80-2.20) 0.281   
Exchange of polyethylene 0.56 (0.31-1.02) 0.059 - -  0.75 (0.46-1.21) 0.234    0.45 (0.26-0.77) 0.033 0.44 (0.26-0.76) 0.003 
Need for ≥ 2 debridements 1.16 (0.57-2.36) 0.683    2.26 (1.63-4.36) <0.001 2.45 (1.45-4.15) 0.001  0.60 (0.26-1.40) 0.206   
Antimicrobial therapy‡               
 Β-lactams (without rifampin) -    -    1.41 (0.88-2.27) 0.155    0.62 (0.37-1.03) 0.061 0.48 (0.28-0.84) 0.010 
  β-lactams + rifampin -    -    0.89 (0.47-1.70) 0.724    0.42 (0.18-0.98) 0.025 0.34 (0.12-0.96) 0.041 
 Quinolones + rifampin -    -    0.19 (0.03-1.36) 0.082 0.21 (0.03-1.54) 0.125  1.03 (0.45-2.40) 0.940   
 Glycopeptides without rifampin -    -    3.97 (2.08-7.58) <0.001 2.82 (1.43-5.53) 0.003  4.25 (1.32-13.7) 0.015 - - 
 Duration of therapy > 120 days -    -    - -    0.54 (0.29-0.90) 0.046 - - 
OR: odds ratio; aOR: adjusted odds ratio; 95%CI: 95% confidence interval; HR: hazard ratio; aHR: adjusted hazard ratio. †Time to debridement: time from onset of 
symptoms to the first surgical debridement. Initial models of multivariate analyses were built with variables with a P value <0.10 in the univariate analysis, and then 
selected with a stepwise backward process. 
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a
 Early Failure: the initial multivariate model included age, rheumatoid arthritis, late post-surgical infections, Rx signs of infection, infection by S. pyogenes, and 
bacteremia. 
b
 Late Failure: the initial multivariate model included sex, rheumatoid arthritis, immunosuppressant therapy, chronic renal disease, infection by S. viridians, time to 
debridement, need for ≥ 2 debridements, treatment with quinolones plus rifampin, and treatment with glycopeptides without rifampin. ‡ Treatments included in this 
analysis are those received during the first 30 days after debridement, and are considered if they were administered for at least 15 days. 
c
 Failure After Therapy: the initial  multivariate model included prosthesis location, late post-surgical infection, Rx signs of infection,  exchange of removable 
components (i.e. polyethylene liner), treatment with beta-lactams (without rifampin), treatment with beta-lactams plus rifampin, and treatment with glycopeptides 
without rifampin. ‡ Treatments included in this analysis are those received during the whole period of treatment, both orally and intravenously, and are considered if 
they were administered for at least 22 days. 
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Figure 1 
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Figure 2 
 
 
